Overview

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Status:
Not yet recruiting

Trial end date:
2025-01-01

Target enrollment:

Participant gender:

Summary

Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in advanced liver cirrhosis, defined by the presence of medically controlled ascites.

Phase:

Phase 3

Details

Lead Sponsor:

Bausch Health Americas, Inc.

Treatments:

Rifaximin